 |
| Ligand ID: 2UO Drugbank ID: DB06693(Mevastatin) Indication:Not used therapeutically due to its many side effects. |
| DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
|---|---|---|---|---|---|---|---|---|---|---|
 Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 2ahm | REPLICASEPOLYPROTEIN 1AB,HEAVY CHAIN (SARSr-CoV) | 5 / 9 | PRO E 126ILE E 111THR E 146VAL E 191ALA E 193 | 1.31A | 18.89 | GOL E2001 (-4.4A)NoneNoneNoneNone | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 2ghw | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO A 324VAL A 382ALA A 331VAL A 497ALA A 384 | 1.45A | 17.72 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 2jw8 | NUCLEOCAPSID PROTEIN (SARSr-CoV) | 5 / 9 | PRO B 259ILE A 338ALA A 314VAL B 271ALA B 265 | 1.66A | 14.22 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 2xyq | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 9 | VAL A 67ILE A 282VAL A 259ALA A 258THR A 257 | 1.67A | 19.37 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 2xyv | PUTATIVE 2'-O-METHYLTRANSFERASE (SARSr-CoV) | 5 / 9 | VAL A 67ILE A 282VAL A 259ALA A 258THR A 257 | 1.67A | 19.50 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3d0g | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO F 324VAL F 382ALA F 331VAL F 497ALA F 384 | 1.52A | 17.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3d0h | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO F 324VAL F 382ALA F 331VAL F 497ALA F 384 | 1.52A | 17.97 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3d0i | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO F 324VAL F 382ALA F 331VAL F 497ALA F 384 | 1.49A | 18.99 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3iwm | 3C-LIKE PROTEINASE (SARSr-CoV) | 5 / 9 | PRO B 252VAL B 247ILE D 213VAL B 296ALA D 210 | 1.67A | 18.35 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3scj | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO F 324VAL F 382ALA F 331VAL F 497ALA F 384 | 1.66A | 16.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3sck | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO F 324VAL F 382ALA F 331VAL F 497ALA F 384 | 1.43A | 18.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 3scl | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO E 324VAL E 382ALA E 331VAL E 497ALA E 384 | 1.51A | 17.75 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5c8s | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 9 | VAL D 244VAL D 182ALA D 85VAL D 282ALA D 281 | 1.69A | 22.45 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 5 / 9 | VAL B 244VAL B 182ALA B 85VAL B 282ALA B 281 | 1.56A | 22.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5f22 | NSP8 (SARSr-CoV) | 5 / 9 | PRO B 126ILE B 111THR B 146VAL B 191ALA B 193 | 1.33A | 15.33 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5nfy | POLYPROTEIN 1AB (SARS-COVFrankfurt1) | 5 / 9 | VAL C 244VAL C 182ALA C 85VAL C 282ALA C 281 | 1.59A | 23.27 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5x4s | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | PRO A 28ILE A 72THR A 236VAL A 98ALA A 233 | 1.55A | 19.74 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5x5b | SPIKE GLYCOPROTEIN (SARS-COVBJ01) | 5 / 9 | PRO B 324VAL B 382ALA B 331VAL B 497ALA B 384 | 1.53A | 16.95 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 5xlr | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | VAL A 606ILE A 520VAL A 537THR A 535VAL A 308 | 1.59A | 17.17 | VAL A 606 ( 0.6A)ILE A 520 ( 0.7A)VAL A 537 ( 0.6A)THR A 535 ( 0.8A)VAL A 308 ( 0.6A) | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6acg | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | VAL A1047VAL A1043ALA A1037THR A 856VAL A 860 | 1.56A | 17.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6crv | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 9 | VAL B1047VAL B1043ALA B1037THR B 856VAL B 860 | 1.69A | 17.19 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6crx | SPIKEGLYCOPROTEIN,FIBRITIN (SARSr-CoV) | 5 / 9 | VAL A1047VAL A1043ALA A1037THR A 856VAL A 860 | 1.56A | 17.22 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6m17 | SODIUM-DEPENDENTNEUTRAL AMINO ACIDTRANSPORTER B(0)AT1 (Homosapiens) | 5 / 9 | VAL A 586ILE A 597ALA A 117THR A 121ALA A 590 | 1.49A | 19.54 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6nb7 | SPIKE GLYCOPROTEIN (SARSr-CoV) | 5 / 9 | VAL B1047VAL B1043ALA B1037THR B 856VAL B 860 | 1.60A | 16.68 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6nb8 | S230 ANTIGEN-BINDING(FAB) FRAGMENT,HEAVY CHAIN (Homosapiens) | 5 / 9 | VAL H 93ALA H 92THR H 91VAL H 12ALA H 10 | 1.40A | 17.17 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6nur | NSP12 (SARSr-CoV) | 5 / 9 | PRO A 328VAL A 398ILE A 536ALA A 376ALA A 382 | 1.49A | 17.81 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6nur | NSP8 (SARSr) | 5 / 9 | PRO D 121ILE D 106THR D 141VAL D 186ALA D 188 | 1.36A | 17.18 | None | ||
| Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site. | 4OQR_A_2UOA502_1 (CYP105AS1) | 6vw1 | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 9 | PRO F 337VAL F 395ALA F 344VAL F 511ALA F 397 | 1.67A | 21.41 | None |